IL-15 is recognized as a promising candidate for tumor immunotherapy and has been described as both a promoter of cancer and a promoter of anti-cancer immunity. IL-15 was discovered in cells transformed by HTLV-1, the etiologic agent of adult T cell leukemia/lymphoma (ATL) and the human retrovirus that carries the Tax oncogene. We have developed the TAX-LUC mouse model of ATL in which Tax expression drives both malignant transformation and luciferase expression, enabling non-invasive imaging of tumorigenesis in real time. To identify the role of IL-15 in spontaneous development of lymphoma in vivo, an IL-15 2/2 TAX-LUC strain was developed and examined. The absence of IL-15 resulted in aggressive tumor growth and accelerated mortality and demonstrated that IL-15 was not required for Tax-mediated lymphoma but was essential for anti-tumor immunity. Further analysis revealed a unique transcriptional profile in tumor cells that arise in the absence of IL-15 that included a significant increase in the expression of IL-1a and IL-1a-regulated cytokines. Moreover, anti-IL-1a antibodies and an IL-1 receptor antagonist (Anakinra) were used to interrogate the potential of IL-1a targeted therapies in this model. Taken together, these findings identify IL-15 and IL-1a as therapeutic targets in lymphoma.
Introduction

The Dual Role of IL-15 in Hematopoietic Malignancies
IL-15 is a central cytokine in lymphocyte development, hematopoietic malignancies, and immunotherapy, where it has paradoxically been described as both a promoter of cancer and a promoter of anti-cancer immunity. [1, 2] IL-15 belongs to the family of four-helix-bundle cytokines (also including IL-2, IL-4, IL-7, IL-9, and IL-21) which use receptors that share a common gamma-c chain and have unique alpha chains. While there is partial redundancy among this family of cytokines, IL-15 has emerged as one particularly suited for antitumor activity. IL-15 is an important factor in the development, homeostasis, proliferation, and activity of CD8 + T cells, NK cells, NKT cells, and intraepithelial T cells. [3] IL-15 also activates monocytes, macrophages, and dendritic cells; inhibits apoptosis in granulocytes and lymphocytes; promotes a persistent immune response without inducing T reg activity; and represents a prime candidate for facilitating innate and durable adaptive tumor immunity. [2] .
Although IL-15 is regarded as an excellent candidate for tumor therapy, it has also been characterized as a promoter of cancer. Co-discovered in HuT-102 cells transformed by HTLV-1 [4, 5] , subsequent studies have confirmed the importance of IL-15 in a variety of hematopoietic malignancies and solid tumors. The potential mechanisms by which IL-15 mediates its pro-tumor activity include protecting tumor cells from apoptosis, and promoting proliferation, migration, invasion and metastasis. [6, 7] IL-15 is an important mediator of growth, and survival of the malignant cells in hematopoietic malignancies and solid tumors. [6, 8, 9] In fact, overexpression of IL-15 in transgenic mice is sufficient to cause CD8 leukemia and T-LGL or NKT leukemia. [10, 11] While IL-15 over-expression promotes leukemia/lymphoma, it is less well understood if IL-15 is a necessary prerequisite for cancer development. Similarly, IL-15 has the potential to be a high-value therapeutic target. What is less clear is whether systemic modulation of IL-15 activity represses or stimulates hematopoietic malignancies in vivo.
TAX-LUC Mice as a Model of Human Lymphoma
HTLV-1, the etiologic agent of adult T cell leukemia/ lymphoma (ATL), is a human retrovirus that carries the Tax oncogene. Tax activates viral transcription through the 59 long terminal repeat (LTR) but is also capable of constitutively activating the NFkB pathway in infected cells which results in overexpression of IL-15. [5, 12] As a model of ATL, TAX transgenic mice, in which Tax expression is governed by the human granzyme B promoter, develop large granular lymphocytic lymphoma. [13] The TAX-LUC strain is a second generation model developed to take advantage of Tax as a strong activator of viral transcription through the HTLV-1 LTR. [14] A transgene in which firefly luciferase is driven by the HTLV-1 LTR (LTR-LUC) was introduced to make double transgenic TAX-LUC mice. Therefore, in TAX-LUC mice, Tax expression drives both tumorigenesis and luciferase expression, which can be detected non-invasively using bioluminescence imaging. Lymphoma in this model presents as subcutaneous tumors, massive splenomegaly, involvement of the bone marrow resulting in hypercalcemia and osteolytic bone lesions, and a chronic inflammatory response involving the persistent activation and recruitment of neutrophils to the tumor. [14, 15] 
Results
IL-15 is Not Required for Lymphomagenesis
The Tax oncogene in TAX-LUC mice is regulated by the granzyme B promoter and drives tumorigenesis and transformation of CD16 HI large granular lymphocytes. IL-15 expression is known to be elevated in these tumors [16] but the role of IL-15 and its effect on the tumor is unclear. To ascertain the function of IL-15 in Tax lymphoma, we created IL15 2/2 TAX-LUC mice and observed that IL-15 is not required for tumor onset or growth. Instead, mice lacking IL-15 had a slightly accelerated rate of tumor onset (FIG. 1A) and a significantly increased mortality rate (FIG. 1B) (FIG. 1F) as is typically seen in TAX-LUC mice. [14] The most distinctive aspects of Tax-tumors were conserved even in the absence of IL-15 including splenomegaly, osteolytic bone lesions, a predominant admixture of tumor infiltrating Ly6G + neutrophils (FIG. 1D) , and constitutive NFkB activity within the malignant LGLs (FIG. 1E ). These data demonstrate that IL-15 has a dramatic effect on survival but is not required for Tax-induced tumorigenesis such that neither the type of malignancy, nor the distinctive characteristics of the tumor model were modified by the absence of IL-15.
IL-15 Represses Tumor Growth
Instead of exposing the cytokine as a necessity for tumor development, the absence of IL-15 dramatically accelerated tumor growth (FIG. 2A) . Luciferase expression resulting from Tax activity in the large tumors (FIG. 2B) (FIG. 2H, FIG. S2 2 cells in the tumor microenvironment. It is also noteworthy that, unlike IL-1b, the elevated levels of IL-1a in normal skin keratinocytes was sufficiently high in this assay to mask any quantifiable effect of IL-15 on IL-1a protein expression within the underlying tumor. Thus, proliferating in the context of significantly reduced numbers of NK and CD8 cells, the malignant population of CD16/32
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LGLs within IL-15 2/2 tumors expressed elevated IL-1a and IL1a-regulated transcripts and recruited activated tumor-infiltrating neutrophils.
Loss of IL-15 Exposes IL-1a as a Regulator of Tumor Growth and Potential Therapeutic Target
Elevated levels of tumor-cell associated IL-1a protein were present in formalin-fixed paraffin embedded sections of IL-15 2/2 tumors (Fig. 4A, Fig. S2 ). Interestingly, IL-1a abundance in the skin surrounding the tumor was independent of IL-15. If IL-1a expression in tumor cells is elevated in the absence of IL-15-dependent cell-mediated immunity, and it contributes to tumor cell death in the context of a competent immune system, we asked if IL-1a could be used as a therapeutic target. Two approaches were used to interrogate the potential of IL-1a targeted therapies in this model. In one experiment, neutralizing anti-IL-1a antibodies were administered to IL-15 +/+ TAX-LUC mice and over the course of treatment, tumor growth was reduced compared to vehicle (FIG. 4B) . Examination of anti-IL-1a treated tumors upon necropsy revealed an increase in tumor infiltrating CD4 + and CD8 + T cells and a decrease in the populations of both malignant LGLs and neutrophils. The antibody-based therapy could be inhibiting IL-1a signaling and/or may be targeting tumor cells for antibody dependent cell cytotoxicity (ADCC). To distinguish between these possibilities, Anakinra, a recombinant form of the IL-1 receptor antagonist, was administered to tumor bearing mice to block IL-1 signaling (FIG. 4C) . In this experiment, two distinct responses were observed. Anakinra was tumoristatic in 7 of 9 tumors resulting in elevated percentages of CD4 + and CD8 + T cells and fewer tumor-associated neutrophils. However, in 2 of 9 tumors, Anakinra treatment resulted in accelerated tumor growth, higher numbers of LGLs, and had no effect on CD4 + T cells or neutrophils. These data identify IL-1a and IL-1 signaling as potential therapeutic targets.
Discussion
This study was designed to determine whether IL-15 expression is a necessary prerequisite for lymphoma development in this mouse model, and whether systemic modulation of IL-15 activity is more likely to repress or stimulate similar malignancies in vivo.
In the absence of IL-15, TAX-LUC mice developed larger, more aggressive tumors that resulted in accelerated mortality. The increase in tumor growth was transiently reversed in the presence of soluble IL-15 and the dearth of NK and CD8
+ T cells in IL-15 2/2 mice is the likely cause of this phenotype. Interestingly, rapid tumor growth immediately followed the growth inhibitory effects of soluble IL-15 leaving open the possibility that administration of IL-15 may simultaneously promote tumor cell growth and cell mediated tumor immunity in vivo.
While IL-15 was clearly not required for tumor growth in this model, IL-15 was essential for anti-tumor immunity. Because IL-15 is required for production of functional NK and CD8
+ T cells, this model was not intended to distinguish between the effects of functional defects in NK and CD8
+ T cells versus lack of recruitment. Instead, the tumor environment in IL-15 2/2 mice, with reduced selective pressure of cellular cytotoxicity, revealed an unexpected transcriptional profile in the malignant cells that is apparently masked by tumor immunity. These masked targets carry potential as biomarkers capable of recruiting or activating an anti-tumor immune response. This study revealed one such target in the malignant cells to be IL-1a.
IL-1a and Tumor Immunity
While IL-1a and IL-1b can have similar biological activities in recombinant or secreted form, these closely related cytokines seem to play very different roles in tumor immunology. [18] IL-1b is active only as a secreted product but IL-1a is also active in its cellassociated forms, as an intracellular precursor or in its membrane bound forms. Membrane-associated IL-1a can signal in a juxtracrine manner [19] and is highly immunostimulatory, [20] capable of activating CTL and NK cells and promoting antitumor immunity and tumor regression. [21] [22] [23] [24] In the absence of cell-mediated immunity both IL-1a and IL-1b promote tumor growth. [25] However in an immune-competent host, IL-1a appears to be a key regulator of innate immunosurveillance mechanisms that promote cell-mediated repression of malignancy. [24, 26] IL-1b, on the other hand, leads to immune suppression of the host by activation and recruitment of T reg cells and CD11b
+ immature myeloid cells and it promotes systemic inflammation, tumor invasiveness and tumor angiogenesis. [21, 22, 27] .
Intracellular IL-1a carries a nuclear localization signal in its Nterminus and is a chromatin associated cytokine [28] that can regulate gene expression by binding the p300-PCAF complex and activating genes in the NFkB and AP-1 pathways. [29, 30] Intracellular IL-1a can also be released during cell necrosis, where its receptor-interacting C-terminus is capable of recruiting infiltrating myeloid cells. [28] Under hypoxic conditions, HIF-1a regulates IL-1-dependent recruitment of myeloid cells [31] such that IL-1a expression correlates with the infiltration of neutrophils, whereas IL-1b is associated with the recruitment of macrophages. [28, 32] In sum, IL-1a and IL-1b are unique therapeutic targets and cell-associated IL-1a is well-suited to serve as a tumor biomarker, CTL adjuvant, and target for antibody or complement-mediated cellular cytotoxicity. mice (red line, n = 13) and IL-15 +/2 TAX-LUC mice (blue line, n = 14) to IL-15 +/+ TAX-LUC littermate control mice (black line, n = 10 
IL-1a and HTLV Tax
Two striking characteristics of ATLL are the long period of latency that usually precedes disease onset and the low penetrance of ATL among infected carriers. Among the mechanisms thought to underlie these characteristics, one major factor is the role of CTL and host immunity. [33, 34] It has been established that the Tax oncogene is an antigenic target of the adaptive immune response in HTLV-1 infected individuals. [35] Tax is also known to activate the IL-1a promoter, [36] several mouse models have demonstrated elevated levels of IL-1a in response to Tax expression, [13, 17, 37] and HTLV-1+ T cell clones produce high levels of IL-1a in culture. [38] Interestingly, Tax expression is largely restricted or absent in primary ATL cells [39, 40] and the same is true for IL-1a. [41] Compared to IL-1b, IL-1a is also less abundant in primary tissue samples of other human malignancies including melanoma, colon carcinoma, and non-small cell lung carcinoma. [42] These data are consistent with the hypothesis that there is a selection against IL-1a expression in ATL cells, and other malignancies, in vivo. Our data provides a mechanistic explanation for these observations in ATL. Tax activity leads to IL-1a expression which recruits and activates cell-mediated killing of IL-1a -expressing, HTLV-1 infected cells. This is corroborated by the fact that depletion of IL-1a in a Tax transgenic mouse model reduced Tax-induced autoimmunity. [43] What remains to be determined is whether IL-1a-directed therapies can enhance killing of HTLV infected cells in vivo, reduce viral load, or target Tax-dependent mechanisms of ATL progression.
Translational Implications of IL-15 and IL-1a
IL-15 is already recognized as a promising candidate for tumor immunotherapy. [1, 2] The principle findings in this study are that IL-15 is critical in the inhibition of tumor growth in this model and that IL-1a expression is targeted by IL-15-dependent anti-tumor activity (FIG. 5) . Taken together these findings provide a rationale for testing IL-15, an anti-IL-1a antibody or a combination of both in lymphoma. The combination of IL-15 and cetuximab increased ADCC activity against triple negative breast cancer cell lines and enhanced cetuximab efficacy against HER1-positive head and neck cancer. [44, 45] IL-15 has also been shown to enhance rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells. [46] Moreover, the combination of IL-15 and anti-CD40 is more efficacious than either therapy alone in mouse models of metastatic colon cancer or metastatic renal cell carcinoma. [47] [48] [49] An anti-IL-1a monoclonal antibody (MABp1, Xbiotech) is currently undergoing clinical trials for treatment of advanced leukemia and other cancers, and has shown evidence of anti-tumor activity. [50] Alone and in combination, IL-15 and anti-IL-1a therapies are worth exploring against hematopoietic malignancies.
Materials and Methods
Animals
IL-15
2/2 mice on a C57BL/6 background (3, Taconic) were intercrossed with TAX-LUC transgenic mice on a C57BL/ 66FVB background. [14] The use of murine models and tissues in this study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Mice were housed under pathogen-free conditions according to the guidelines of the Division of Comparative Medicine and all experiments were approved by the Animal Studies Committee, Washington University School of Medicine under ASC protocol #20100026.
Histology and Immunohistochemistry
Tumor or organ tissue was fixed in 10% buffered formalin and paraffin-embedded sections were processed for immunohistochemical stains. Slides were heated to 55 o C for 10 minutes, deparaffinized in xylene, and rehydrated in deionized water. For antigen retrieval/unmasking, slides were boiled (under pressure) in citric acid buffer (pH 6) for 15 minutes and allowed to cool to room temperature. In some cases, slides were also treated with proteinase K (20 ug/mL in TE, pH 8) for 2 minutes at room temperature, and washed with PBS. Endogenous peroxidase activity was blocked by incubating the slides in 0.3% hydrogen peroxide solution for 5 minutes. For Ki67 staining, slides were then blocked in normal equine serum (Jackson ImmunoResearch Laboratories Inc.) for 15 minutes and rinsed. Slides were soaked in rabbit polyclonal anti-Ki67 (Vector Laboratories) overnight at 4uC. Slides were then washed and incubated in ImmPRESS reagent anti-rabbit IgG (Vector Laboratories) for 30 minutes at room temperature, incubated in DAB peroxidase substrate, rinsed, and coverslipped. TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) staining was conducted according to manufacturer's protocol (Trevigen). For CD16/32 staining additional blocking steps with avidin D solution (Vector Laboratories) and for 15 min at room temp, followed by biotin for 15 minutes at room temperature was included prior to incubation in primary biotin rat anti-mouse CD16/32 antibody (BD Pharmingen) overnight at 4uC. Rabbit polyclonal anti-PCNA (abcam), rabbit monoclonal anti-phosphoRel-A (Cell Signaling Technology Inc), rat anti-mouse Ly6G (eBioscience), and goat polyclonal anti-rat IL-1a (Santa Cruz biotechnology, Inc) primary antibodies were used. Negative controls lacking primary antibody were included for each stain. Sections were visualized with a Nikon Eclipse E400 microscope and digital images were obtained using a Magnafire camera and software (Optronics). 
Treatment Regimens
Bioluminescent Imaging
The IVIS100 system (Xenogen) was used to image bioluminescence in anesthetized mice (isoflurane inhalation). 
Protein Array
Tail tumors and normal tail tissue from IL-15 2/2 and IL-15
TAX-LUC mice were excised and homogenized in PBS with protease inhibitors (10 mg/mL Aprotinin, 10 mg/mL Leupeptin, and 10 mg/mL Pepstatin) and Triton X-100 was added to a final concentration of 1%. Samples were then frozen at 280uC, thawed, centrifuged at 10,0006g for 5 minutes to remove cellular debris, quantified, and analyzed using a Proteome Profiler Mouse Cytokine Antibody Array (R&D Systems) according to manufacturer's instructions.
RT-PCR
2 mg of RNA obtained from sorted cells was subjected to DNase I digestion (Invitrogen) and RT-PCR was carried out using SuperScript III First-Strand Synthesis system (Invitrogen) according to manufacturer's instructions. 100 ng of cDNA template was used for each reaction. Qualitative RT-PCR was performed using a two-phase, step-down PCR method; 16 cycles of 94uC for 30 s, 64uC (20.5uC/cycle) for 30 s, 72uC for 30 s, followed by 10 cycles of 94uC for 30 s, 56uC for 30 s, 72uC for 30.
Western Blot
Tumor cells harvested from IL-15 2/2 and IL-15 +/+ TAX-LUC mice were centrifuged, rinsed, resuspended in RIPA buffer, sonicated, boiled in SDS buffer for 15 min, and run on 15% SDS-PAGE at 4uC. Blots were probed using a rabbit anti-Tax primary antibody. 
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